Efficacy and safety of antibody-drug conjugates for HR+/HER2-low advanced breast cancer: a systematic review with Bayesian network meta-analysis and real-world study.

Although DCR showed a favorable trend, but the difference was insignificant (RR =1.17, 95% CI: 0.98–1.40) ( Figure 3E ).

also in 993 other papers

In terms of tumor response, T-DXd showed a numerical trend toward being the top-ranked intervention (SUCRA: ORR 0.819; DCR 0.803; CBR 0.833) and demonstrated statistically significant improvements compared to TPC in both DCR (RR =0.32; 95% CI: 0.11–0.88) and CBR (RR =3.60; 95% CI: 1.06–12.60); while T-DXd also numerically outperformed SG in ORR, DCR, and CBR, these pairwise differences were not statistically significant ( Figure 6 and Table 2 ).

also in 723 other papers

With regards to safety, T-DXd exhibited lowest occurrence of grade ≥ AEs, whereas SG showed a relatively higher rate, although pairwise differences did not reach statistical significance.

also in 75,281 other papers